321 related articles for article (PubMed ID: 34054828)
1. The Role of IL-36 in Infectious Diseases: Potential Target for COVID-19?
Wang X; Yi P; Liang Y
Front Immunol; 2021; 12():662266. PubMed ID: 34054828
[TBL] [Abstract][Full Text] [Related]
2. Insights into IL-37, the role in autoimmune diseases.
Xu WD; Zhao Y; Liu Y
Autoimmun Rev; 2015 Dec; 14(12):1170-5. PubMed ID: 26264940
[TBL] [Abstract][Full Text] [Related]
3. A new target for the treatment of inflammatory bowel disease: Interleukin-37.
Jia Y; Anwaar S; Li L; Yin Z; Ye Z; Huang Z
Int Immunopharmacol; 2020 Jun; 83():106391. PubMed ID: 32208166
[TBL] [Abstract][Full Text] [Related]
4. Coronavirus-19 (SARS-CoV-2) induces acute severe lung inflammation via IL-1 causing cytokine storm in COVID-19: a promising inhibitory strategy.
Conti P; Caraffa A; Gallenga CE; Ross R; Kritas SK; Frydas I; Younes A; Ronconi G
J Biol Regul Homeost Agents; 2020; 34(6):1971-1975. PubMed ID: 33016027
[TBL] [Abstract][Full Text] [Related]
5. An overview of the biological and multifunctional roles of IL-38 in different infectious diseases and COVID-19.
Fazeli P; Saeidnia M; Erfani M; Kalani M
Immunol Res; 2022 Jun; 70(3):316-324. PubMed ID: 35260945
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-36 in Infectious and Inflammatory Skin Diseases.
Buhl AL; Wenzel J
Front Immunol; 2019; 10():1162. PubMed ID: 31191535
[TBL] [Abstract][Full Text] [Related]
7. [Recent progress in the pathophysiological role of interleukin-19].
Fujimoto Y; Azuma YT
Nihon Yakurigaku Zasshi; 2019; 154(2):66-71. PubMed ID: 31406045
[TBL] [Abstract][Full Text] [Related]
8. The novel interleukin-1 cytokine family members in inflammatory diseases.
Hahn M; Frey S; Hueber AJ
Curr Opin Rheumatol; 2017 Mar; 29(2):208-213. PubMed ID: 27926540
[TBL] [Abstract][Full Text] [Related]
9. The emergence of the IL-36 cytokine family as novel targets for inflammatory diseases.
Walsh PT; Fallon PG
Ann N Y Acad Sci; 2018 Apr; 1417(1):23-34. PubMed ID: 27783881
[TBL] [Abstract][Full Text] [Related]
10. How to reduce the likelihood of coronavirus-19 (CoV-19 or SARS-CoV-2) infection and lung inflammation mediated by IL-1.
Conti P; Gallenga CE; Tetè G; Caraffa A; Ronconi G; Younes A; Toniato E; Ross R; Kritas SK
J Biol Regul Homeost Agents; 2020 March-April,; 34(2):333-338. PubMed ID: 32228825
[TBL] [Abstract][Full Text] [Related]
11. Role of Interleukin-37 in Inflammatory and Autoimmune Diseases.
Wang X; Xu K; Chen S; Li Y; Li M
Iran J Immunol; 2018 Sep; 15(3):165-174. PubMed ID: 30246692
[TBL] [Abstract][Full Text] [Related]
12. IL-37 As a Potential Biotherapeutics of Inflammatory Diseases.
Bai J; Li Y; Li M; Tan S; Wu D
Curr Drug Targets; 2020; 21(9):855-863. PubMed ID: 32348214
[TBL] [Abstract][Full Text] [Related]
13. Dual Immune Regulatory Roles of Interleukin-33 in Pathological Conditions.
Guo H; Bossila EA; Ma X; Zhao C; Zhao Y
Cells; 2022 Oct; 11(20):. PubMed ID: 36291105
[TBL] [Abstract][Full Text] [Related]
14.
Mardi A; Meidaninikjeh S; Nikfarjam S; Majidi Zolbanin N; Jafari R
Viral Immunol; 2021 Dec; 34(10):679-688. PubMed ID: 34882013
[TBL] [Abstract][Full Text] [Related]
15. The potential role of interleukin-37 in infectious diseases.
Allam G; Gaber AM; Othman SI; Abdel-Moneim A
Int Rev Immunol; 2020; 39(1):3-10. PubMed ID: 31633447
[TBL] [Abstract][Full Text] [Related]
16. Mast cells activated by SARS-CoV-2 release histamine which increases IL-1 levels causing cytokine storm and inflammatory reaction in COVID-19.
Conti P; Caraffa A; Tetè G; Gallenga CE; Ross R; Kritas SK; Frydas I; Younes A; Di Emidio P; Ronconi G
J Biol Regul Homeost Agents; 2020 Sep-Oct,; 34(5):1629-1632. PubMed ID: 32945158
[TBL] [Abstract][Full Text] [Related]
17. IL-18 and infections: Is there a role for targeted therapies?
Vecchié A; Bonaventura A; Toldo S; Dagna L; Dinarello CA; Abbate A
J Cell Physiol; 2021 Mar; 236(3):1638-1657. PubMed ID: 32794180
[TBL] [Abstract][Full Text] [Related]
18. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies.
Conti P; Ronconi G; Caraffa A; Gallenga CE; Ross R; Frydas I; Kritas SK
J Biol Regul Homeost Agents; 2020 March-April,; 34(2):327-331. PubMed ID: 32171193
[TBL] [Abstract][Full Text] [Related]
19. IL-17 and IL-17R: an auspicious therapeutic target for psoriatic disease.
Mitra A; Raychaudhuri SK; Raychaudhuri SP
Actas Dermosifiliogr; 2014 Oct; 105 Suppl 1():21-33. PubMed ID: 25398489
[TBL] [Abstract][Full Text] [Related]
20. IL-19 as a potential therapeutic in autoimmune and inflammatory diseases.
Azuma YT; Nakajima H; Takeuchi T
Curr Pharm Des; 2011 Nov; 17(34):3776-80. PubMed ID: 22103848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
